The online home for the primary care professionals managing patients with cardiovascular disease, diabetes and related diseases.

Sacubitril/valsartan: the first ARNI

Sacubitril/valsartan: the first ARNI

Publication date: Friday, 21 October 2016
Contributor(s): Ameet Bakhai, Michael Kirby

This article gives an overview of sacubitril/valsartan (Entresto), a first-in-class angiotensin receptor-neprilysin inhibitor comprising valsartan, an angiotensin II receptor blocker and the neprilysin inhibitor sacubitril. The drug has been approved for the treatment of symptomatic (NYHA class (II-IV) chronic heart failure and reduced ejection fraction (HF-REF) in adults.

Sponsorship information:
This sponsored supplement was initiated and funded by Novartis. Novartis reviewed the supplement for technical accuracy and suitability within the ABPI Code of Practice. Final editorial control rests with the authors and editors.
Topics covered:
Category: Editorial
Edition: Volume 9 Number 1 Oct-Nov-Dec 2016
Contributor(s): Ameet Bakhai, Michael Kirby

Article search and filter